NASDAQ:VCNX

Vaccinex Earnings Date & Estimates

Vaccinex logo
$1.02 +0.02 (+2.00%)
As of 11:56 AM Eastern

Vaccinex is estimated to report earnings on Wednesday, November 18, 2026.

What Analysts Expect from Vaccinex

Vaccinex is expected to post earnings of -$73.0380 per share on revenue of $333 thousand.

Consensus Estimates

Consensus EPS
-$73.0380
Expected Revenue
$333 thousand

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
-$3.10
Last Quarter Revenue
$230 thousand

Vaccinex Earnings FAQ

Vaccinex (NASDAQ:VCNX) is estimated to report earnings on Wednesday, November 18, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Vaccinex to post earnings of -$73.0380 per share for the quarter.

The consensus revenue estimate for Vaccinex is $333 thousand for the quarter.

Vaccinex Earnings Headlines

Vaccinex (VCNX) Projected to Announce Quarterly Earnings on Monday
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Vaccinex Reports 2025 Annual Financial Results
See More Vaccinex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email.

About Vaccinex

Vaccinex (NASDAQ:VCNX) is a biotechnology company focused on developing antibody-based treatments for cancer and neurological diseases. Its research centers on semaphorin 4D (SEMA4D), a protein involved in immune regulation and tissue responses.

The company’s lead drug candidate, pepinemab, is an investigational monoclonal antibody designed to block SEMA4D. Vaccinex has studied the treatment in clinical programs for conditions including cancer and Huntington’s disease; it does not have an approved commercial product.

Based in Rochester, New York, Vaccinex was founded in 2001. Its work has also included the ActivMAb platform, a technology for discovering and developing therapeutic antibodies.

View Vaccinex Profile